Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

BACKGROUND: Patients with recurrent glioblastoma (rGB) have a poor prognosis with a median overall survival (OS) of 30–39 weeks in prospective clinical trials. Intravenous administration of programmed cell death protein 1 and cytotoxic T-lymphocyte-associated antigen 4 inhibitors has low activity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Duerinck, Johnny, Schwarze, Julia Katharina, Awada, Gil, Tijtgat, Jens, Vaeyens, Freya, Bertels, Cleo, Geens, Wietse, Klein, Samuel, Seynaeve, Laura, Cras, Louise, D’Haene, Nicky, Michotte, Alex, Caljon, Ben, Salmon, Isabelle, Bruneau, Michaël, Kockx, Mark, Van Dooren, Sonia, Vanbinst, Anne-Marie, Everaert, Hendrik, Forsyth, Ramses, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231061/
https://www.ncbi.nlm.nih.gov/pubmed/34168003
http://dx.doi.org/10.1136/jitc-2020-002296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231061/
https://www.ncbi.nlm.nih.gov/pubmed/34168003
http://dx.doi.org/10.1136/jitc-2020-002296

Ejemplares similares